Today, phase 3 data published in The New England Journal of Medicine (NEJM) set the stage for the future of care for children under 12 with severe #hemophilia A. Learn more about what these results mean for this population. Read our press release: http://spkl.io/60464CTmO NEJM Group
Kudos to the dedicated researchers and medical professionals driving innovation in pediatric care.
As fas as i understand, there are no severe site effects observed fo far an it is harmless to children at 6 years of age. The painful bleeding into joits is reduced by more than 95% by one injection weeklly. Great work I love the recent emphasis on rare diseases.
Nice
These are such informative insights. 🙌
Incredible work 🙏🏼
Love this 😍
It's a great news that Sanofi and Sobi help the children suffered from hemophilia A.
Fantastic work!
Global Head of Medical Affairs Rare Diseases
1moThis is important news for children with #hemophilia A and their caregivers. When we focus our efforts holistically on the outcomes that are most important to people affected by the condition, we have the potential to meaningfully transform care. Congratulations to the authors and the Sanofi Medical and Clinical teams for this milestone, and thank you to the participants who made this study possible. Alicia Mack, PharmD, Jennifer Dumont, Annemieke Willemze, Cecile Le Camus